Product Description
CRB-601 is a potent and selective alphavb8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment. (Sourced from: https://www.corbuspharma.com/press-releases/detail/368/corbus-presents-first-preclinical-data-for-crb-601-at-the)
Mechanisms of Action: aVb8 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Corbus
Company Location: NORWOOD MA 02062
Company CEO: Yuval Cohen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CRB-601-01 | P2 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2026-11-01 |